Sequential cleavages of the amyloid -protein precursor (APP) by the -and ␥-secretases generate the amyloid -protein (A), which plays a central role in Alzheimer's disease. Previous work provided evidence for involvement of both the secretory and endocytic pathways in A generation. Here, we used HeLa cells stably expressing a tetracycline-regulated dominant-negative dynamin I (dyn K44A), which selectively inhibits receptor-mediated endocytosis, and analyzed the effects on the processing of endogenous APP. Upon induction of dyn K44A, levels of mature APP rose at the cell surface, consistent with retention of APP on the plasma membrane. The ␣-secretase cleavage products of APP were increased by dyn K44A, in that ␣-APPs in medium and the C83 C-terminal stub in the membrane both rose. The -secretase cleavage of APP, C99, also increased modestly. The use of specific ␥-secretase inhibitors to study the accumulation of ␣-and -cleavage products independent of their processing by ␥-secretase confirmed that retention of APP on the plasma membrane results in increased processing by both ␣-and -secretases. Unexpectedly, endogenous A secretion was significantly increased by dyn K44A, as detected by three distinct methods: metabolic labeling, immunoprecipitation/ Western blotting, and enzyme-linked immunosorbent assay. Levels of p3 (generated by sequential ␣-and ␥-cleavage) also rose. We conclude that endogenous A can be produced directly at the plasma membrane and that alterations in the degree of APP endocytosis may help regulate its production. Our findings are consistent with a role for the ␥-secretase complex in the processing of numerous single-transmembrane receptors at the cell surface.Genetic, neuropathological, biochemical, and animal modeling studies all suggest that the progressive accumulation of the amyloid -protein (A) 1 in limbic and association cortices initiates Alzheimer's disease. Such evidence has recently led to the development of therapeutic agents aimed at decreasing the production or enhancing the clearance of A. Despite this progress, a central unresolved question remains: precisely where in the cell is A generated from the membrane-anchored amyloid -protein precursor (APP)? This question has taken on greater interest with emerging evidence that APP appears to function as a cell surface receptor that can undergo regulated intramembrane proteolysis (RIP) (1, 2). Sequential cleavage of APP by the aspartyl proteases BACE/ -secretase and presenilin/␥-secretase releases A into the lumen/extracellular space and liberates the APP intracellular domain into the cytoplasm in a process strikingly similar to the cleavage of the Notch receptors that enables their signaling in myriad cell fate decisions (2-4). An increasing number of cell surface proteins, including nectin-1␣ (5), CD44 (6), LRP (7), E-cadherin (8), andErbB4 (9), has been discovered to undergo RIP, with some of these releasing intracellular domains that may function as transcriptional regulators. Thus, the processing of APP by RIP, ...